{"protocolSection": {"identificationModule": {"nctId": "NCT00855738", "orgStudyIdInfo": {"id": "A0081144"}, "secondaryIdInfos": [{"id": "LICEO STUDY"}], "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice", "officialTitle": "Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice"}, "statusModule": {"statusVerifiedDate": "2010-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-05"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-03", "studyFirstSubmitQcDate": "2009-03-03", "studyFirstPostDateStruct": {"date": "2009-03-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-06-23", "resultsFirstSubmitQcDate": "2010-06-23", "resultsFirstPostDateStruct": {"date": "2010-07-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-21", "lastUpdatePostDateStruct": {"date": "2021-01-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy."}, "conditionsModule": {"conditions": ["Focal Epilepsy"], "keywords": ["epilepsy antiepileptic biotherapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 111, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1.0", "type": "OTHER", "interventionNames": ["Drug: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide"]}], "interventions": [{"type": "DRUG", "name": "Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide", "description": "* Gabapentin: up to 3.600 mg/d\n* Lamotrigine: up to 400 mg/d\n* Levetiracetam: up to 3.000 mg/d\n* Pregabalin: up to 600 mg/d\n* Oxcarbazepine: up to 2.400 mg/d\n* Tiagabine: up to 30 mg/d\n* Topiramate: up to 400 mg/d\n* Zonisamide: up to 500 mg/d", "armGroupLabels": ["1.0"], "otherNames": ["Neurontin, Lamictal, Lyrica, Keppra, Topamax, Gabatril, Episen, Zonegran"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent of Participants Classified as Responders", "description": "Responder = decrease in number of seizures by \\>=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)"}], "secondaryOutcomes": [{"measure": "Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment", "description": "Percent of participants with reduction in number of seizures \\>=25% and \\>=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)"}, {"measure": "Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)"}, {"measure": "Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)"}, {"measure": "Percent of Days Without Crisis During the Study", "description": "Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.", "timeFrame": "Baseline through Month 6 (or end of treatment)"}, {"measure": "Time to First Seizure", "description": "Number of days to first seizure after baseline.", "timeFrame": "Baseline to Month 6 (or end of treatment)"}, {"measure": "Percent of Participants Who Continued on Study Medication to Month 6", "description": "Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.", "timeFrame": "Baseline to Month 6"}, {"measure": "Time to Discontinuation Due to Lack of Efficacy", "timeFrame": "Baseline, Month 3, Month 6"}, {"measure": "Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance", "timeFrame": "Baseline, Month 3, Month 6"}, {"measure": "Time to Discontinuation Due to Other Reasons", "timeFrame": "Baseline, Month 3, Month 6"}, {"measure": "Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)", "description": "Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).", "timeFrame": "Baseline, Month 3, Month 6"}, {"measure": "Percent of Participants Reaching Monotherapy", "description": "Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.", "timeFrame": "Baseline through Month 6 (or end of study)"}, {"measure": "Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)", "timeFrame": "Baseline to Month 6 (or end of treatment)"}, {"measure": "Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy", "timeFrame": "Baseline through Month 6 (or end of treatment)"}, {"measure": "Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)", "description": "HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.", "timeFrame": "Baseline to Month 6"}, {"measure": "Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)", "description": "QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.", "timeFrame": "Baseline to Month 6"}, {"measure": "Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)", "description": "Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.", "timeFrame": "Baseline, Month 3, Month 6"}, {"measure": "Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)", "description": "Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).", "timeFrame": "Baseline to Month 6"}, {"measure": "Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)", "description": "MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.", "timeFrame": "Baseline, Month 6"}, {"measure": "Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy", "description": "Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.", "timeFrame": "Baseline to Month 6"}, {"measure": "Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy", "description": "Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.", "timeFrame": "Baseline to Month 6"}, {"measure": "Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit", "description": "Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).", "timeFrame": "Month 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18 years or older.\n* Diagnosis of focal epilepsy.\n* Previous failure of one or more AEDs used in monotherapy.\n* Background treatment with an antiepileptic drug.\n* The investigator has considered that the patient must start treatment with some of the seven new AEDs in combination therapy: lamotrigine, levetiracetam, gabapentin, oxcarbazepine, pregabalin, tiagabine and/or topiramate.\n* History of seizures in the patient in the past 3 months.\n* The patient or legal guardian must be able to understand the characteristics of the study and fill in the seizure diaries.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Inability to comply with the study requirements.\n* Diagnosis of generalized epilepsy or inability to establish if focal or generalized.\n* Presence of serious or uncontrolled systemic disease, serious psychiatric disease or progressive neurological disease.\n* History of alcoholism, drug addiction, or abuse of medicines in the past two years.\n* Psychogenic seizures in the two years prior to inclusion in the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081144&StudyName=A%20Prospective%2C%20Observational%20Study%20On%20The%20Effectiveness%20Of%20New%20Antiepileptic%20Drugs%20As%20First%20Bitherapy%20In%20The%20Daily%20Clinical%20Practice"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Given the observational nature of the study, the selection of treatment and dose of study medication was independent from participation in the study and was determined by daily clinical practice.", "groups": [{"id": "FG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}]}, {"type": "At Least 1 Dose and 1 Endpoint", "achievements": [{"groupId": "FG000", "comment": "Received at least 1 dose of study drug and had data for at least 1 efficacy endpoint.", "numSubjects": "108"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "106"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Subject Defaulted", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.3", "spread": "16.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "52"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "59"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent of Participants Classified as Responders", "description": "Responder = decrease in number of seizures by \\>=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).", "populationDescription": "Full Analysis Set (FAS): intent-to-treat population = those who took at least 1 dose of study medication and had post-baseline data for at least 1 efficacy endpoint. Last Observation Carried Forward (LOCF) captures last 3 months of treatment for subjects who discontinued between Month 3 and Month 6 only. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}]}], "classes": [{"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.7", "lowerLimit": "66.6", "upperLimit": "84.9"}]}]}, {"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.0", "lowerLimit": "70.2", "upperLimit": "87.7"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Month 3: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 6: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment", "description": "Percent of participants with reduction in number of seizures \\>=25% and \\>=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.", "populationDescription": "FAS; LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}]}], "classes": [{"title": "Month 3: >=25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.7", "lowerLimit": "77.9", "upperLimit": "92.9"}]}]}, {"title": "Month 3: >=75%", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.8", "lowerLimit": "18.8", "upperLimit": "38.2"}]}]}, {"title": "Month 6: >= 25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.7", "lowerLimit": "77.9", "upperLimit": "92.9"}]}]}, {"title": "Month 6: >=75%", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.4", "lowerLimit": "43.6", "upperLimit": "65.0"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Month 3 \\>=25% reduction: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 3 \\>=75% reduction: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 6: \\>=25% reduction: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 6: \\>=75% reduction: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation", "populationDescription": "FAS; LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}]}], "classes": [{"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.0", "lowerLimit": "4.7", "upperLimit": "18.1"}]}]}, {"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.0", "lowerLimit": "12.3", "upperLimit": "29.8"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Month 3: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0039", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 6: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment", "populationDescription": "FAS LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Month 3, Month 6 (last 3 months of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-75.0", "lowerLimit": "-88.9", "upperLimit": "-50.0"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "Wilcoxon Signed Rank Test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent of Days Without Crisis During the Study", "description": "Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.", "populationDescription": "The percentage of days without crisis during the study was not evaluable because a diary with the daily number of crises was not collected.", "reportingStatus": "POSTED", "timeFrame": "Baseline through Month 6 (or end of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Time to First Seizure", "description": "Number of days to first seizure after baseline.", "populationDescription": "FAS LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Baseline to Month 6 (or end of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.9", "spread": "40.2"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Participants Who Continued on Study Medication to Month 6", "description": "Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.", "populationDescription": "FAS; LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97.1"}]}]}]}, {"type": "SECONDARY", "title": "Time to Discontinuation Due to Lack of Efficacy", "populationDescription": "FAS; LOCF. As no participants discontinued due to lack of efficacy, the time to exit analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Month 3, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance", "populationDescription": "FAS; LOCF. Due to the low number of participants who discontinued due to safety, tolerability or compliance with treatment, the time to exit analysis was not performed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Month 3, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Time to Discontinuation Due to Other Reasons", "populationDescription": "FAS; LOCF. Due to the low number of participants who discontinued due to other reasons, the time to exit analyses was not performed.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Month 3, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)", "description": "Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).", "populationDescription": "FAS; LOCF. The scale for this endpoint was not collected and results were not analyzed as planned.", "reportingStatus": "POSTED", "timeFrame": "Baseline, Month 3, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percent of Participants Reaching Monotherapy", "description": "Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.", "populationDescription": "FAS; LOCF. N=number of participants who started on bitherapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of partipants", "timeFrame": "Baseline through Month 6 (or end of study)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "lowerLimit": "0.6", "upperLimit": "8.1"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)", "populationDescription": "FAS; LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline to Month 6 (or end of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"title": "Reduced", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "lowerLimit": "0.0", "upperLimit": "5.1"}]}]}, {"title": "Maintained", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.5", "lowerLimit": "58.9", "upperLimit": "77.1"}]}]}, {"title": "Increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.6", "lowerLimit": "22.1", "upperLimit": "40.2"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy", "populationDescription": "FAS; LOCF. N= number of subjects with initial treatment administered as monotherapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline through Month 6 (or end of treatment)", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "classes": [{"title": "Reduced", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}]}]}, {"title": "Maintained", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0"}]}]}, {"title": "Increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)", "description": "HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.", "populationDescription": "FAS; LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on scale", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}]}], "classes": [{"title": "Depression", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "3.5"}]}]}, {"title": "Anxiety", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "3.0"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Depression domain: P-value vs baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.1797", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Anxiety domain: P-value vs baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0433", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)", "description": "QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.", "populationDescription": "FAS; LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on scale", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}]}], "classes": [{"title": "Energy", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "17.8"}]}]}, {"title": "Emotions (mood)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "16.0"}]}]}, {"title": "Daily activities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "12.9"}]}]}, {"title": "Mental function", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "20.8"}]}]}, {"title": "Medication effects (physical/ mental)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "14.9"}]}]}, {"title": "Worry about seizures (impact of seizures)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.0", "spread": "21.1"}]}]}, {"title": "Overall quality of life", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "17.2"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Energy: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8284", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Emotions (mood): p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.6299", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Daily activities: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.6162", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Mental function: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.5609", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Medication effects (physical/ mental): p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4635", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Worry about seizures (impact of seizures): p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Overall quality of life: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0258", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)", "description": "Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.", "populationDescription": "FAS LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on scale", "timeFrame": "Baseline, Month 3, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "16.2"}]}]}, {"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "15.6"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Month 3: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.7822", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Month 6: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4471", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)", "description": "Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).", "populationDescription": "FAS LOCF. Change from baseline in Optimal sleep is not shown as changes from baseline were only evaluated for continuous parameters. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on scale", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}]}], "classes": [{"title": "Sleep disturbance", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "spread": "15.1"}]}]}, {"title": "Snoring", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "15.6"}]}]}, {"title": "Awake short of breath", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "14.6"}]}]}, {"title": "Quantity", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "0.8"}]}]}, {"title": "Adequacy", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "15.0"}]}]}, {"title": "Somnolence", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "11.0"}]}]}, {"title": "Sleep problems (summary 6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "11.7"}]}]}, {"title": "Sleep problems (summary 9)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "13.2"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Sleep disturbance: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.2452", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Snoring: p-value verus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "1.0000", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Awake short of breath: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4253", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Quantity: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0572", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Adequacy: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0625", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Somnolence: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.5540", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Sleep problems (summary 6): p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4204", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Sleep problems (summary 9): p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4869", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)", "description": "MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.", "populationDescription": "FAS; LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "Baseline, Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.5"}]}]}, {"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.7"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Month 6: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0863", "statisticalMethod": "McNemar", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy", "description": "Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.", "populationDescription": "FAS; LOCF. Costs involved in health and non-health resources needed during the study were not analyzed as planned with this endpoint. N=number of subjects with visits to a specialist because of epilepsy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "visits", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"title": "Number of visits to a specialist (n=94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "2.3"}]}]}, {"title": "Number of visits to the emergency room (n=79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.9"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Number of visits to a specialist because of epilepsy: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0226", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Number of visits to the emergency room because of epilepsy: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0017", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy", "description": "Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.", "populationDescription": "FAS; LOCF. N=number of subjects with evaluable data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Baseline to Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.0", "spread": "68.6"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "P-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.3141", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit", "description": "Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).", "populationDescription": "FAS; LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "Month 6", "groups": [{"id": "OG000", "title": "All Antiepileptic Drugs", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"title": "Stopped Usual Occupation", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.2"}]}]}, {"title": "Required Informal Caregiver", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.6"}]}]}, {"title": "Required Admission to ICU", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Cessation of usual occupation: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0708", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Requirement of informal caregiver: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "1.0000", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Required admission to ICU: p-value versus baseline.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "1.0000", "statisticalMethod": "t-test, 2 sided", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Includes data from baseline to 7 days after last dose of study drug.", "description": "Safety Population: subjects known to have taken at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "All Antiepileptic Drugs (Including Pregabalin)", "description": "Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin", "seriousNumAffected": 0, "seriousNumAtRisk": 111, "otherNumAffected": 7, "otherNumAtRisk": 111}, {"id": "EG001", "title": "Pregabalin (Pregabalin Only)", "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 5, "otherNumAtRisk": 40}], "otherEvents": [{"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 40}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 40}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 40}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 40}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was cancelled with 111 patients enrolled due to lack of recruitment, and inability to analyze the study by treatment groups. Seizures were analyzed by 3 month data instead of 2 month data as originally planned."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000004828", "term": "Epilepsies, Partial"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M7984", "name": "Epilepsies, Partial", "asFound": "Focal Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077236", "term": "Topiramate"}, {"id": "D000069583", "term": "Pregabalin"}, {"id": "D000077213", "term": "Lamotrigine"}, {"id": "D000078305", "term": "Zonisamide"}, {"id": "D000077206", "term": "Gabapentin"}, {"id": "D000077287", "term": "Levetiracetam"}, {"id": "D000078308", "term": "Tiagabine"}], "ancestors": [{"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014151", "term": "Anti-Anxiety Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018691", "term": "Excitatory Amino Acid Antagonists"}, {"id": "D000018683", "term": "Excitatory Amino Acid Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000018692", "term": "Antimanic Agents"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000018697", "term": "Nootropic Agents"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000058805", "term": "GABA Uptake Inhibitors"}, {"id": "D000014179", "term": "Neurotransmitter Uptake Inhibitors"}, {"id": "D000018682", "term": "GABA Agents"}], "browseLeaves": [{"id": "M1694", "name": "Gabapentin", "asFound": "Pregnant", "relevance": "HIGH"}, {"id": "M1741", "name": "Levetiracetam", "asFound": "Deliver", "relevance": "HIGH"}, {"id": "M476", "name": "Pregabalin", "asFound": "Reality", "relevance": "HIGH"}, {"id": "M1949", "name": "Zonisamide", "asFound": "AZA", "relevance": "HIGH"}, {"id": "M1711", "name": "Topiramate", "asFound": "Instrument", "relevance": "HIGH"}, {"id": "M1701", "name": "Lamotrigine", "asFound": "Muscle strength", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M1958", "name": "Oxcarbazepine", "relevance": "LOW"}, {"id": "M1951", "name": "Tiagabine", "asFound": "Acinetobacter", "relevance": "HIGH"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M16905", "name": "Anti-Anxiety Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M20771", "name": "Excitatory Amino Acid Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M20774", "name": "Nootropic Agents", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NootAg", "name": "Nootropic Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}